Phase I/II trial of perioperative avelumab in combination with chemoradiation (CRT) in the treatment of stage II/III resectable esophageal and gastroesophageal junction (E/GEJ) cancer.

被引:0
|
作者
Uboha, Nataliya Volodymyrivna
Eickhoff, Jens C.
Maloney, James D.
McCarthy, Daniel
DeCamp, Malcolm
Deming, Dustin A.
LoConte, Noelle K.
Matkowskyj, Kristina A.
Patel, Monica Arun
Hurst, Newton
Kratz, Jeremy D.
Lubner, Sam Joseph
Bassetti, Michael Frederick
机构
[1] UW Carbone Canc Ctr, Madison, WI USA
[2] Univ Wisconsin, Dept Biostat, Madison, WI USA
[3] Univ Wisconsin, Div Cardiothorac Surg, Dept Surg, Madison, WI USA
[4] Univ Wisconsin, Madison, WI USA
[5] ECOG ACRIN, Madison, WI USA
[6] Univ Michigan, Ann Arbor, MI USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
4034
引用
收藏
页数:1
相关论文
共 50 条
  • [21] Randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.
    Rahma, Osama E.
    Katz, Matthew H. G.
    Wolpin, Brian M.
    Dias-Costa, Andressa
    Nowak, Jonathan
    Rodig, Scott J.
    Dougan, Stephanie
    Bekaii-Saab, Tanios S.
    Stucky, Chee-Chee H.
    Elias, Rawad
    Petroni, Gina R.
    Bauer, Todd W.
    Slingluff, Craig L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] A phase II trial of preoperative one cycle of induction chemotherapy [capecitibine (CAP), CDDP] followed by concurrent chemoradiation (CRT) in patients (pts) with resectable esophageal cancer.
    Kim, SB
    Park, SI
    Kim, JH
    Jung, HY
    Lee, GH
    Park, JH
    Ahn, JH
    Cho, KJ
    Song, HY
    Min, YI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 323S - 323S
  • [23] Chemoradiation with raltitrexed in preoperative treatment of stage II/III resectable rectal cancer: long term results of a phase II study
    Gambacorta, M. A.
    Valentini, V.
    Giammarino, D.
    Balducci, M.
    Ciresa, M.
    Montoro, C.
    Marazzi, F.
    Pacelli, F.
    Ratto, C.
    Doglietto, G. B.
    EJC SUPPLEMENTS, 2005, 3 (02): : 193 - 193
  • [24] Multicenter phase II study of neoadjuvant nivolumab or nivolumab plus relatlimab (anti-LAG3 antibody) plus chemoradiotherapy in stage II/III esophageal/gastroesophageal junction (E/GEJ) carcinoma
    Kelly, Ronan Joseph
    Zaidi, Ali Hussainy
    Canzoniero, Jenna VanLiere
    Feliciano, Josephine Louella
    Hales, Russell K.
    Voong, K. Ranh
    Battafarano, Richard James
    Jobe, Blair Anderson
    Yang, Stephen
    Broderick, Stephen
    Ha, Jinny Suk
    Smith, Kellie Nicole
    Thompson, Elizabeth D.
    Shaikh, Fyza
    Shin, Eun Ji
    Amjad, Ali Imran
    Guerrieri, Patrizia
    Hu, Chen
    Anagnostou, Valsamo
    Lam, Vincent K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [25] A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study
    Menglong Zhou
    Wang Yang
    Yan Xuan
    Wei Zou
    Yaqi Wang
    Zhiyuan Zhang
    Jing Zhang
    Miao Mo
    Changming Zhou
    Yuan Liu
    Wenming Zhang
    Zhaozhen Zhang
    Yiping He
    Weiwei Weng
    Cong Tan
    Lei Wang
    Dan Huang
    Weiqi Sheng
    Huanhuan Li
    Hui Zhu
    Yan Wang
    Lijun Shen
    Hui Zhang
    Juefeng Wan
    Guichao Li
    Hua Huang
    Yanong Wang
    Zhen Zhang
    Xiaowen Liu
    Fan Xia
    BMC Cancer, 22
  • [26] A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study
    Zhou, Menglong
    Yang, Wang
    Xuan, Yan
    Zou, Wei
    Wang, Yaqi
    Zhang, Zhiyuan
    Zhang, Jing
    Mo, Miao
    Zhou, Changming
    Liu, Yuan
    Zhang, Wenming
    Zhang, Zhaozhen
    He, Yiping
    Weng, Weiwei
    Tan, Cong
    Wang, Lei
    Huang, Dan
    Sheng, Weiqi
    Li, Huanhuan
    Zhu, Hui
    Wang, Yan
    Shen, Lijun
    Zhang, Hui
    Wan, Juefeng
    Li, Guichao
    Huang, Hua
    Wang, Yanong
    Zhang, Zhen
    Liu, Xiaowen
    Xia, Fan
    BMC CANCER, 2022, 22 (01)
  • [27] Perioperative sintilimab combination with SOX for resectable locally advanced gastric/gastroesophageal junction cancer(GC/GEJC): Initial findings of a single-arm phase II trial
    Ding, Xuewei
    Li, Bin
    Xue, Qiang
    Cai, Mingzhi
    Cui, Jingli
    Wang, Baogui
    Ke, Bin
    Zhang, Rupeng
    Liang, Han
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [28] A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in-A trial of the ECOG-ACRIN Cancer Research Group (EA2174).
    Eads, Jennifer Rachel
    Weitz, Michelle
    Catalano, Paul J.
    Gibson, Michael K.
    Rajdev, Lakshmi
    Khullar, Onkar
    Lin, Steven H.
    Gatsonis, Constantine
    Wistuba, Ignacio Ivan
    Sanjeevaiah, Aravind
    Benson, Al Bowen
    Bahary, Nathan
    Spencer, Kristen Renee
    Saba, Nabil F.
    Hamilton, Stanley R.
    Staley, Charles A.
    Chakravarthy, Bapsi
    Fisher, George A.
    Wong, Terence Z.
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Phase II trial of postoperative concurrent chemoradiotherapy (CCRT) for poor-prognosis cancer of the esophagus and gastroesophageal junction (GEJ)
    Adelstein, D. J.
    Rice, T. W.
    Rybicki, L. A.
    Saxton, J. P.
    Videtic, G. M.
    Murthy, S. C.
    Mason, D. P.
    Rodriguez, C. P.
    Ives, D. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] Chemoradiation with raltitrexed and oxaliplatin in pre-operative treatment of stage II/III resectable rectal cancer: long term results of a phase II studies
    Gambacorta, M. A.
    Valentini, V.
    Mantini, G.
    Salvi, G.
    Petrone, A.
    Mattiucci, G. C.
    Barba, M. C.
    Verbo, A.
    Crucitti, A.
    Coco, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 194 - 194